SCHEMBL22214360

SCHEMBL22214360

CC(C)(C)OC(=O)N1[C@@]2(C)CC[C@]1(C)C/C(=N\O)C2

nearest known ligand 0.35

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
BUB1 O43683 1/20 0.35
ALDH1A1 P00352 2/20 0.34
USP2 O75604 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
NR1H2 P55055 1/20 0.32
FAAH O00519 1/20 0.31
CHRM2 P08172 1/20 0.31
CHRM1 P11229 1/20 0.31
CHRM3 P20309 1/20 0.31
KDM1A O60341 1/20 0.30
LMNA P02545 1/20 0.30
MAPT P10636 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20704993 1.00 BUB1 (0.35) BUB1ALDH1A1USP2SMN1; SMN2NR1H2
SCHEMBL20712674 0.85 BUB1 (0.34) BUB1USP2SMN1; SMN2NR1H2FAAH
SCHEMBL22313865 0.83 BUB1 (0.33) BUB1
SCHEMBL20705097 0.82 BUB1 (0.40) BUB1ALDH1A1USP2SMN1; SMN2NR1H2
SCHEMBL22214352 0.82 BUB1 (0.40) BUB1ALDH1A1USP2SMN1; SMN2NR1H2
SCHEMBL20704991 0.76 ALDH1A1 (0.41) ALDH1A1
SCHEMBL29431708 0.76 USP2 (0.38) BUB1USP2SMN1; SMN2NR1H2FAAH
SCHEMBL16414303 0.76 BUB1 (0.39) BUB1USP2SMN1; SMN2NR1H2FAAH
SCHEMBL16419900 0.75 BUB1 (0.35) BUB1ALDH1A1USP2SMN1; SMN2NR1H2
SCHEMBL30968059 0.75 CHRM2 (0.35) BUB1NR1H2CHRM2CHRM1CHRM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230059865-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2023-02-23 US disclosed
US-20220403383-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2022-12-22 US disclosed
US-11326165-B1 Methods and compositions for modulating splicing SKYHAWK THERAPEUTICS, INC. (US) 2022-05-10 US disclosed
US-11162101-B2 Methods and compositions for modulating splicing SKYHAWK THERAPEUTICS, INC. (US) 2021-11-02 US disclosed
US-11091475-B2 Methods and compositions for modulating splicing SKYHAWK THERAPEUTICS, INC. (US) 2021-08-17 US disclosed
US-20210171519-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2021-06-10 US disclosed
US-11021708-B2 Methods and compositions for modulating splicing SKYHAWK THERAPEUTICS, INC. (US) 2021-06-01 US disclosed
US-11008572-B2 Methods and compositions for modulating splicing SKYHAWK THERAPEUTICS, INC. (US) 2021-05-18 US disclosed
US-20200277289-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2020-09-03 US disclosed
US-20200247799-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2020-08-06 US disclosed
US-20200224199-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2020-07-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11326165-B1 Methods and compositions for modulating splicing RBM17, SF3B1, SNRPA1 BUB1 3104/4885ALDH1A1 4181/4885USP2 2509/4885
US-11021708-B2 Methods and compositions for modulating splicing RBM17, SF3B1, SNRPA1 BUB1 3104/4885ALDH1A1 4181/4885USP2 2509/4885
US-20210171519-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING RBM17, SF3B1, SNRPA1 BUB1 3104/4885ALDH1A1 4181/4885USP2 2509/4885
US-20200247799-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING RBM17, SF3B1, SNRPA1 BUB1 3104/4885ALDH1A1 4181/4885USP2 2509/4885
US-20220403383-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING RBM17, SF3B1, SNRPA1 BUB1 3104/4885ALDH1A1 4181/4885USP2 2509/4885
US-11008572-B2 Methods and compositions for modulating splicing RBM17, SF3B1, SNRPA1 BUB1 3104/4885ALDH1A1 4181/4885USP2 2509/4885
US-11162101-B2 Methods and compositions for modulating splicing RBM17, SF3B1, SNRPA1 BUB1 3104/4885ALDH1A1 4181/4885USP2 2509/4885
US-11091475-B2 Methods and compositions for modulating splicing RBM17, SF3B1, SNRPA1 BUB1 3104/4885ALDH1A1 4181/4885USP2 2509/4885
US-20200277289-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING RBM17, SF3B1, SNRPA1 BUB1 3104/4885ALDH1A1 4181/4885USP2 2509/4885
US-20230059865-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING RBM17, SF3B1, SNRPA1 BUB1 3104/4885ALDH1A1 4181/4885USP2 2509/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.